News

Article

ABVC BioPharma reaches global licensing deal for ophthalmology pipeline

Author(s):

The company announced it has entered into a global licensing agreement with ForSeeCon Eye Corp. for the company's ophthalmology pipeline, which includes the medical device Vitargus.

(Image Credit: AdobeStock/Tn)

(Image Credit: AdobeStock/Tn)

ABVC BioPharma announced the company and its subsidiary BioFirst Corp entered into a global licensing agreement with ForSeeCon Eye Corp (FEYE) for the company's ophthalmology pipeline, which includes the medical device Vitargus.

According to a news release, Vitargus is valued at $187 million by a third-party valuer. The license will cover the Licensed Products' clinical trial, registration, manufacturing, supply, and distribution rights.1

Uttam Patil, CEO of ABVC, said in the news release the company believes the deal will make its products available to more patients undergoing the vitrectomy procedure.

“This partnership underscores our commitment to providing patients with a better quality of life during and after the procedure," Patil said in the news release.

Patil added that through this collaboration, ABVC has secured the distribution rights to a wide range of eye products from ForSeeCon, which he said he believes will provide a new avenue for revenue generation with access to an even broader audience.

With the licensing agreement in place, ABVC will continue to serve as the R&D partner of ForSeeCon to discover new pipelines for ophthalmic products. From better vitreous substitutes to various eyecare products, our platform remains dedicated to showcasing the best eyecare we can offer.

ABVC will receive the first licensing payment of US$30,000,000 (cash/shares) within 30 days after executing the agreement. ABVC is entitled to another milestone payment of $3,500,000 in cash after the first useful fundraise and royalties of 5% of net sales, up to $60,000,000, after the launch of the Licensed Product. BioFirst is entitled to the same licensing fees and royalties as ABVC.1

Jerry Chang, CEO of ForSeeCon Eye said his company is pleased to work on Vitargus, representing its commitment to innovation.

“This product is a game-changer, and I'm confident it will exceed our customers' expectations,” he said in the news release.

Chang added that the therapeutic could set a new standard.

“We certainly believe that with the launch of this product, we're not just introducing a new item to the market; we're reshaping it,” he said. “Its unique features and capabilities will revolutionize how our customers engage with ForSeeCon and elevate their overall experience," he added.

According to iHealthcare Analyst, Inc., the global market for retinal surgery devices is expected to reach $4.3 billion by 2029, at a CAGR of 7.7%, driven partly by the rising geriatric population worldwide.2

References
1. Inc AB. ABVC BioPharma Entered into a Global Licensing Deal of Vitargus with Licensing Income of $33.5M and Royalties up to $60M. GlobeNewswire News Room. Published March 26, 2024. Accessed March 27, 2024. https://www.globenewswire.com/news-release/2024/03/26/2852346/0/en/ABVC-BioPharma-Entered-into-a-Global-Licensing-Deal-of-Vitargus-with-Licensing-Income-of-33-5M-and-Royalties-up-to-60M.html
2. Inc iHealthcareAnalyst. Global Retinal Surgery Devices Market $5.1 Billion by 2031. iHealthcareAnalyst, Inc. - Healthcare Market Research. Published January 4, 2024. Accessed March 27, 2024. https://www.ihealthcareanalyst.com/technological-advancement-ophthalmic-surgery-retinal-surgery-devices-market/

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
Patricia Buehler, MD, MPH, founder and CEO of Osheru, talks about the Ziplyft device for noninvasive blepharoplasty at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Bonnie An Henderson, MD, on leveraging artificial intelligence in cataract refractive surgery
(Image credit: Ophthalmology Times) ASCRS 2025: Gregory Moloney, FRANZO, FRCSC, on rotational stability
Sheng Lim, MD, FRCOphth, discusses the CONCEPT study, which compared standalone cataract surgery to cataract surgery with ECP, at the 2025 ASCRS Annual Meeting.
(Image credit: Ophthalmology Times) ASCRS 2025: Steven J. Dell, MD, reports 24-month outcomes for shape-changing IOL
© 2025 MJH Life Sciences

All rights reserved.